Raziel Therapeutics

Company Overview

Snapshot

Founded in August 2012, Raziel Therapeutics operates with 1–10 employees. The company has raised $27.1M across 5 funding rounds from 9 investors. In October 2025, Peregrine Ventures participated in a funding round for Raziel Therapeutics.

Business overview

Raziel Therapeutics is a clinical-stage pharmaceutical company focused on developing a proprietary injectable drug for targeted fat reduction. The company's core technology involves a new chemical entity, RZL-012, designed to convert white adipose tissue into brown adipose tissue after a single injection, aiming to treat overweight and obese individuals. RZL-012 is currently in preclinical development and works by triggering fat-cell death, which is then replaced by fibrotic tissue, leading to sustained fat tissue shrinkage. Raziel Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, addressing conditions like obesity and Dercum's disease.

Strategic signal

In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc, a leading South Korean medical institution specializing in fat reduction treatments. This partnership aims to accelerate the development of RZL-012 in South Korea, signaling a significant move towards international market expansion and validation of its drug candidate in a key Asian market.

Company Intelligence Q&A

What is Raziel Therapeutics' primary drug candidate?

Raziel Therapeutics' primary drug candidate is RZL-012, an injectable drug currently in preclinical development designed for targeted fat reduction.

When did Raziel Therapeutics receive FDA approval for RZL-012 as an orphan drug?

In November 2019, Raziel Therapeutics received FDA approval to develop RZL-012 as an orphan drug for Dercum's disease.

What was the nature of the collaboration announced in July 2025?

In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc to accelerate the development of RZL-012 in South Korea.

Which investors participated in the February 2016 A Round?

Pontifax and Docor International Management participated in Raziel Therapeutics' A Round in February 2016.